"Cancer Vaccines" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Vaccines or candidate vaccines designed to prevent or treat cancer. Vaccines are produced using the patient's own whole tumor cells as the source of antigens, or using tumor-specific antigens, often recombinantly produced.
| Descriptor ID |
D019496
|
| MeSH Number(s) |
D20.215.894.200
|
| Concept/Terms |
Cancer Vaccines- Cancer Vaccines
- Vaccines, Tumor
- Vaccines, Neoplasm
- Tumor Vaccines
- Vaccines, Cancer
- Neoplasm Vaccines
|
Below are MeSH descriptors whose meaning is more general than "Cancer Vaccines".
Below are MeSH descriptors whose meaning is more specific than "Cancer Vaccines".
This graph shows the total number of publications written about "Cancer Vaccines" by people in this website by year, and whether "Cancer Vaccines" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1996 | 0 | 1 | 1 |
| 1997 | 0 | 1 | 1 |
| 1998 | 3 | 2 | 5 |
| 1999 | 1 | 0 | 1 |
| 2000 | 1 | 2 | 3 |
| 2001 | 4 | 1 | 5 |
| 2002 | 5 | 1 | 6 |
| 2003 | 3 | 5 | 8 |
| 2004 | 2 | 1 | 3 |
| 2005 | 5 | 0 | 5 |
| 2006 | 4 | 0 | 4 |
| 2007 | 2 | 1 | 3 |
| 2008 | 2 | 2 | 4 |
| 2009 | 6 | 4 | 10 |
| 2010 | 9 | 1 | 10 |
| 2011 | 5 | 2 | 7 |
| 2012 | 4 | 2 | 6 |
| 2013 | 4 | 2 | 6 |
| 2014 | 7 | 4 | 11 |
| 2015 | 0 | 1 | 1 |
| 2016 | 2 | 2 | 4 |
| 2017 | 1 | 0 | 1 |
| 2018 | 2 | 1 | 3 |
| 2019 | 7 | 1 | 8 |
| 2020 | 6 | 3 | 9 |
| 2021 | 5 | 0 | 5 |
| 2022 | 2 | 0 | 2 |
| 2023 | 3 | 0 | 3 |
| 2024 | 4 | 1 | 5 |
| 2025 | 1 | 1 | 2 |
To return to the timeline,
click here.
Below are the most recent publications written about "Cancer Vaccines" by people in Profiles.
-
Safety and Tolerability of Letetresgene Autoleucel (GSK3377794): Pilot Studies in Patients with Advanced Non-Small Cell Lung Cancer. Clin Cancer Res. 2025 Feb 03; 31(3):529-542.
-
Lipid nanoparticles deliver DNA-encoded biologics and induce potent protective immunity. Mol Cancer. 2025 Jan 13; 24(1):12.
-
Targeting Siglec-E facilitates tumor vaccine-induced antitumor immunity in renal carcinoma. J Immunother Cancer. 2025 Jan 04; 13(1).
-
Engineering immunity: bacterial delivery of cancer neoantigen vaccines. Trends Immunol. 2024 Dec; 45(12):931-933.
-
IL-2/anti-IL-2 antibody complexes augment immune responses to therapeutic cancer vaccines. Proc Natl Acad Sci U S A. 2024 Nov 26; 121(48):e2322356121.
-
Comparing neoantigen cancer vaccines and immune checkpoint therapy unveils an effective vaccine and anti-TREM2 macrophage-targeting dual therapy. Cell Rep. 2024 Nov 26; 43(11):114875.
-
Therapeutic vaccine targeting dual immune checkpoints induces potent multifunctional CD8+ T cell anti-tumor immunity. Int Immunopharmacol. 2024 Dec 05; 142(Pt A):113004.
-
Development of an engineered extracellular vesicles-based vaccine platform for combined delivery of mRNA and protein to induce functional immunity. J Control Release. 2024 Oct; 374:550-562.
-
B cell-based therapy produces antibodies that inhibit glioblastoma growth. J Clin Invest. 2024 Aug 29; 134(20).
-
Adenovirus vaccine targeting kinases induces potent antitumor immunity in solid tumors. J Immunother Cancer. 2024 Aug 28; 12(8).